BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Algorithme Pharma News - Impaired Renal Function Clinical Trials


11/4/2013 8:45:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

November 04, 2013 -- Algorithme Pharma recently collaborated with Hôpital Maisonneuve-Rosemont (HMR), in a joint clinical trial with the successful enrollment of patients with impaired renal function. Patients with moderate and severe renal impairment were enrolled at the nephrology department at HMR under the supervision of Dr. Vincent Pichette, MD, PhD, nephrologist. In parallel, patients with mild renal impairment were enrolled at Algorithme Pharma, under the supervision of Dr. Eric Sicard, MD, Principal Investigator. A control group of healthy participants with normal renal function were matched (by age, weight, etc.) with renal impaired patients. This was required as a baseline renal function in the assessment of the investigational drug. Full enrollment was completed in 10-weeks and included 24 patients with mild, moderate and severely impaired renal function.

In this trial, the drug was administered at the same dose level to groups with mild, moderate and severely impaired renal function. This allowed for dosage adjustment recommendations to be made for patients based on measures of renal function. The dose levels were classified using the estimated glomerular filtration rate (eGFR) as established by the Food and Drug Administration (FDA) in its guidance for this study type.

Algorithme Pharma has developed strategic relationships with major hospitals in the Greater Montreal area, including multiple external investigators, for the conduct of clinical trials involving varying patient populations. Depending on study requirements, we have the flexibility to conduct the clinical portion of a study at a hospital's clinical research unit, at Algorithme Pharma or both.

For more information, please contact us at:

1 (450) 973-6077

1 (888) 267-7449

contact@algopharm.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES